Precision Microbiota Interventions for Senoreduction Trial
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age40+
SponsorLouisiana State University Health Sciences Center in New Orleans
About this trial
People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
Eligibility criteria
Qualifiers
Age ≥40 years
People with HIV
Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)
Disqualifiers
Probiotic use in past 3 months
Recent antibiotics or immunosuppressives
Allergy to study products
Pregnancy or breastfeeding
Trial design
Treatments tested in this trial
- Limosilactobacillus reuteri
- Blueberry extract
Treatment groups
160 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov